
## Payal Dhar

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/181573/publications.pdf Version: 2024-02-01



<u> Ράνλι Πήλρ</u>

#	Article	IF	CITATIONS
1	CD38-NAD+Axis Regulates Immunotherapeutic Anti-Tumor T Cell Response. Cell Metabolism, 2018, 27, 85-100.e8.	16.2	197
2	NKG2D and its ligands in cancer. Current Opinion in Immunology, 2018, 51, 55-61.	5.5	143
3	Anticancer activity of Ophiobolin A, isolated from the endophytic fungus <i>Bipolaris setariae</i> . Natural Product Research, 2016, 30, 1455-1458.	1.8	33
4	NK Cell Plasticity in Cancer. Journal of Clinical Medicine, 2019, 8, 1492.	2.4	25
5	Antibody targeting tumor-derived soluble NKC2D ligand sMIC provides dual co-stimulation of CD8 T cells and enables sMIC+ tumors respond to PD1/PD-L1 blockade therapy. , 2019, 7, 223.		23
6	Antibody targeting tumor-derived soluble NKG2D ligand sMIC reprograms NK cell homeostatic survival and function and enhances melanoma response to PDL1 blockade therapy. Journal of Hematology and Oncology, 2020, 13, 74.	17.0	17
7	Tumor-derived NKG2D ligand sMIC reprograms NK cells to an inflammatory phenotype through CBM signalosome activation. Communications Biology, 2021, 4, 905.	4.4	10